POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review, the New Drug Application (NDA) for PA32540/PA8140.

Cedars-Sinai Heart Institute is honoring the physician widely known as  the leading pioneer in modern mitral heart valve repair, Alain Carpentier, MD, PhD, with the second annual Eliot Corday, MD, International Prize in Heart Research. The Cedars-Sinai Heart Institute established the Corday Prize to recognize physicians and scientists conducting groundbreaking research, or individuals who significantly advance the practice of heart medicine.

The Billings Gazette in Montana is keeping tabs on a $13.5 million expansion and renovation of surgical facilities at the Billings Clinic. The latest update includes a 3-D illustration of the cardiovascular operating room viewed from various angles.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Thomas M. Abate, the company's chief financial officer, plans to retire later this year. Abate, who turns 60 in August, plans to remain CFO until his successor is in place. The company has retained Peter Crist of Crist/Kolder Associates to assist in the CFO search.

Richard Lifton, MD, PhD, chair of the genetics department at Yale University, and Jonathan R. Kaltman, MD, chief of the Heart Development and Structural Diseases Branch at the National Heart, Lung, and Blood Institute, discuss genetic causes of heart disease in a video.  Findings from the research team’s large-scale sequencing analysis of congenital heart disease were published online May 12 in Nature. 

The American Heart Association and Macy’s have awarded 16 scholarships of $2,500 each to increase culturally-sensitive, patient-centered care.

The New York Times published a feature article that detailed a research effort to unravel the genetic underpinnings of cardiovascular disease. Members of one family with a history of heart-related deaths have agreed to participate in the study.

The Watchman wait may be over. An analysis of long-term data found the Watchman left atrial appendage closure device to be superior to warfarin for primary efficacy and mortality.